<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8610688</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5937</journal-id>
<journal-id journal-id-type="nlm-ta">Mov Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">Mov. Disord.</journal-id>
<journal-title-group>
<journal-title>Movement disorders : official journal of the Movement Disorder Society</journal-title>
</journal-title-group>
<issn pub-type="ppub">0885-3185</issn>
<issn pub-type="epub">1531-8257</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28233916</article-id>
<article-id pub-id-type="pmc">5714315</article-id>
<article-id pub-id-type="doi">10.1002/mds.26902</article-id>
<article-id pub-id-type="manuscript">NIHMS837085</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Iron accumulation and dysregulation in the putamen in fragile X associated tremor/ataxia syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ariza</surname>
<given-names>Jeanelle</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rogers</surname>
<given-names>Hailee</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hartvigsen</surname>
<given-names>Anna</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Snell</surname>
<given-names>Melissa</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dill</surname>
<given-names>Michael</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Judd</surname>
<given-names>Derek</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Paul</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martínez-Cerdeño</surname>
<given-names></given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Pathology and Laboratory Medicine, UC Davis School of Medicine; Institute for Pediatric Regenerative Medicine and Shriners Hospitals for Children of Northern California</aff>
<aff id="A2">
<label>2</label>MIND Institute, UC Davis Medical Center</aff>
<aff id="A3">
<label>3</label>Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine</aff>
<author-notes>
<corresp id="FN1">Corresponding author: Verónica Martínez-Cerdeño, PhD, 2425 Stockton Boulevard; Sacramento, California, 95817, Phone: (916) 453-2163, <email>vmartinezcerdeno@ucdavis.edu</email></corresp>
<fn fn-type="COI-statement" id="FN3">
<p><bold>Conflict of interest:</bold> PJH holds patents for assays of CGG-repeat expansion and for FMRP ELISA; he is also in non-remunerative collaborations with Pacific Biosciences, Inc. and Roche Diagnostics. Authors otherwise declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>4</month>
<year>2018</year>
</pub-date>
<volume>32</volume>
<issue>4</issue>
<fpage>585</fpage>
<lpage>591</lpage>
<!--elocation-id from pubmed: 10.1002/mds.26902-->
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P1">Fragile X-associated tremor/ataxia Syndrome (FXTAS) is an adult-onset disorder associated with premutation alleles of the <italic>FMR1</italic> gene. The disorder is characterized by progressive action tremor, gait ataxia, and cognitive decline. FXTAS pathology includes dystrophic white matter and intranuclear inclusions in neurons and astrocytes. We previously demonstrated that the transport of iron into the brain is altered in FXTAS; therefore, we also expect an alteration of iron metabolism in brain areas related to motor control. Iron is essential for cell metabolism, but uncomplexed iron leads to oxidative stress and contributes to the development of neurodegenerative diseases.</p>
</sec>
<sec id="S2">
<title>Objectives</title>
<p id="P2">We investigated a potential iron modification in the striatum, the structure that participates in motor learning and performance, in FXTAS.</p>
</sec>
<sec id="S3">
<title>Methods</title>
<p id="P3">We used samples of putamen obtained from 9 FXTAS and 9 control cases to study iron localization using Perl’s method, and iron-binding proteins using immunostaining.</p>
</sec>
<sec id="S4">
<title>Results</title>
<p id="P4">We found increased iron deposition in neuronal and glial cells, which accumulate iron, in the putamen in FXTAS. We also found a generalized decreased of the amount of the iron-binding proteins, transferrin and ceruloplasmin, in the putamen, and decreased numbers of neurons and glial cells that contained ceruloplasmin. However, we found increased levels of iron, transferrin, and ceruloplasmin in microglial cells, indicating the attempt by the immune system to remove the excess iron.</p>
</sec>
<sec id="S5">
<title>Conclusions</title>
<p id="P5">Overall, there is a deficit in proteins that eliminate extra iron from the cells with the concomitant increased in the deposit of cellular iron.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Fragile X</kwd>
<kwd>repeat-expansion disorder</kwd>
<kwd>CGG</kwd>
<kwd>dementia</kwd>
<kwd>FXTAS</kwd>
<kwd>neurodegeneration</kwd>
<kwd>motor disorder</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>